CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03473925
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:14.891744+00:00
Published At: 2022-06-29T00:00:00+00:00
Record Updated At: 2024-08-28
Results Posted At: 2022-06-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumors", "Non-small Cell Lung Cancer", "Castration Resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-28"
protocolSection.identificationModule.nctId: "NCT03473925"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-06-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.